China Researcher's CCR5 Knockout Babies Shock World Into New Gene Editing Debate
Executive Summary
A devoted researcher or a shrewd business entrepreneur, whatever you call him, He Jiankui seems to have what it takes to draw the spotlight to his cutting edge gene editing technology, so controversial that even his employer has joined calls to denounce him.
You may also be interested in...
China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race
A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.